SERPINB3 and metabolic dysfunction-associated steatohepatitis: The involvement of SerpinB3 in NAFLD and in its progressive form non-alcoholic steatohepatitis (NASH) is relevant since NAFLD is emerging as the major cause of chronic liver disease worldwide, with epidemiological data indicating a 30 % prevalence in the general population and an even higher prevalence (>70 %) in obese individuals and Type II diabetes patients, which represent the typical NAFLD/NASH patients [5,15].